132 filings
Page 4 of 7
S-8
4a5f x6w50p6o
5 Apr 23
Registration of securities for employees
4:01pm
8-K
x7dvi6 649y5s
31 Mar 23
Disrupting Convention in Women’s Health Through Continuous Innovation March 2023 Corporate Presentation 1
5:03pm
8-K
mg1yk4y36scg
30 Mar 23
Results of Operations and Financial Condition
8:05am
8-K
2zeryyrql cu
13 Mar 23
Other Events
9:28am
8-K
qz9mj98f2nq2bn2g5
21 Dec 22
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
4:01pm
8-K
6ugocfusp5mkly 87kzg
10 Nov 22
Femasys Inc. Announces Financial Results for the Third Quarter Ended Third Quarter and Recent Developments Related to Clinical Programs and Commercial Products
8:35am
8-K
jhcqh a12v3
20 Oct 22
Disrupting Convention in Women’s Health Through Continuous Innovation October 2022 Corporate Presentation 1
8:34am
8-K
ow3hgzrz1di
12 Oct 22
Femasys Inc. Announces the Appointment of Christine Thomas As Senior Vice President of Regulatory and Clinical Affairs
8:46am
8-K
01h9var5de6
6 Oct 22
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control
8:49am
8-K
rgb lrg1iy69e71p2ssq
29 Sep 22
Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team
8:41am
8-K
ddwn3of0je22n
10 Aug 22
Femasys Inc. Announces Financial Results for the Second Quarter Ended Second Quarter and Recent Developments Related to Clinical Programs
4:06pm
8-K
qwim0ev
2 Aug 22
Disrupting Convention in Women’s Health Through Continuous Innovation August 2022 Corporate Presentation 1
5:08pm
EFFECT
x5eywh
13 Jul 22
Notice of effectiveness
12:15am
424B3
mrfh 086557qmvhgwk
12 Jul 22
Prospectus supplement
9:47pm
424B3
8rprkn ior9b
12 Jul 22
Prospectus supplement
4:00pm
S-3
hki6mldwc c8ftbw16q
1 Jul 22
Shelf registration
4:55pm
8-K
4n7x4
9 Jun 22
Submission of Matters to a Vote of Security Holders
4:15pm